Format

Send to

Choose Destination
Vaccine. 2019 Jul 18;37(31):4243-4245. doi: 10.1016/j.vaccine.2019.06.021. Epub 2019 Jun 22.

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.

Author information

1
Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Québec, Canada. Electronic address: genevieve.deceuninck.ciussscn@ssss.gouv.qc.ca.
2
Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada.
3
Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
4
Direction de santé publique de la Région sociosanitaire du Saguenay-Lac-Saint-Jean, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Canada.
5
Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Québec, Canada; Direction des risques biologique et de la santé au travail, Institut national de santé publique du Québec, Quebec City, Québec, Canada; Department of Social and Preventive Medicine, Laval University, Quebec City, Québec, Canada.
6
Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Québec, Canada; Direction des risques biologique et de la santé au travail, Institut national de santé publique du Québec, Quebec City, Québec, Canada; Department of Social and Preventive Medicine, Laval University, Quebec City, Québec, Canada. Electronic address: philippe.dewals@criucpq.ulaval.ca.

Abstract

In the Saguenay-Lac-Saint-Jean region of Quebec, 83% of the population ≤20 years (n ≅ 59,500) was immunized in 2014 with the four-component Serogroup B meningococcal vaccine to control a long-lasting outbreak caused by a virulent ST-269 Serogroup B Neisseria meningitidis clone. Following the campaign, invasive meningococcal B disease (B-IMD) incidence fell sharply in the target population from 11.4/100,000 in 2006-2014 to 0.4/100,000 in 2014-2018 (p < 0.0001). Five B-IMD cases occurred in the region from July 2014 to June 2018, including one vaccinated child, one unvaccinated young adult and 3 unvaccinated elderly adults. Estimate of direct vaccine protection was 79% [95%CI:-231%;99%]. The overall campaign impact in the region taking into account the decrease in B-IMD incidence at provincial level was a 86% [95%CI:-2%;98%] decrease in B-IMD risk. The campaign impact was mostly seen in the target age-group suggesting no herd effect among unvaccinated older adults.

KEYWORDS:

Effectiveness; Immunization; Mass campaign; Meningococcal disease; Meningococcal vaccine

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center